摘要
目的:观察比较亚莫利和美吡哒在老年2型糖尿病患者中的临床疗效及安全性。方法:将60例2型糖尿病患者随机分成亚莫利治疗组和美吡哒治疗组,治疗12周后,观察两种不同治疗方案患者空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(GHbA1)及低血糖发生的情况。结果:(1)2组治疗后FBG、2 hPBG、HbA1c均明显下降(P<0.05),但亚莫利组FBG、GHbA1下降更明显(P<0.05);(2)亚莫利组低血糖发生比例明显低于美吡哒组。结论:亚莫利能更好地降低老年2型糖尿病的血糖水平,尤其是空腹血糖,且低血糖发生率低。
Objective： To compare curative effect and safety of two kinds of suifonylureas in elderly type 2 diabetics. Methods： Sixty patients with type 2 diabetes were randomly divided into Amaryl （glimepiride） group and Minidiab （glipizide） group, which use those two different drugs respectively to decrease blood glucose. After 12 weeks, the two therapeutic regimen were evaluated by fasting blood glucose （FBG）, postprandial 2 h blood glucose （2 h PBG）, GHbAI and low blood sugar occurrence. Results： After the treatment, fasting blood glucose （FBG）, postprandial 2 h blood glucose （2 h PBG） and glycosylated hemoglobin of the two groups both declined significantly （P〈0.05）, but FBG and GHbAl of Amaryl group dropped more markedly （P 〈0.05） ; The incidence rate of hypoglycemia in Amaryl group was much lower than that in Minidiab group. Conclusion： Amaryl was better in reducing blood sugar levels of the elderly with type 2 diabetes than Minidiab, especially in decreasing fasting blood glucose, and it leads to lower incidence rate of hypoglycemia
出处
《新疆医科大学学报》
CAS
2009年第3期296-297,共2页
Journal of Xinjiang Medical University
